This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodés, B.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodés, B.
Right arrow Articles by Soriano, V.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2002, p. 4313-4316, Vol. 40, No. 11
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.11.4313-4316.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Rapid Assessment of Phenotypic Resistance to Protease Inhibitors in Human Immunodeficiency Virus Type 1 Group O

Berta Rodés, Eva Poveda, and Vincent Soriano*

Department of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain

Received 25 February 2002/ Returned for modification 17 June 2002/ Accepted 19 July 2002

A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long exposure to these drugs with respect to baseline. The emergence of PI resistance corresponded to the selection of amino acid changes L10V, G48M, F53L, I54V, and L90M at the protease. The results were concordant with those obtained by a drug susceptibility assay with primary HIV isolates.

* Corresponding author. Mailing address: Calle Nueva Zelanda 54, 4° B, Madrid 28035, Spain. Phone: 34 91 4532500. Fax: 34 91 7336614. E-mail: vsoriano{at}dragonet.es.

Journal of Clinical Microbiology, November 2002, p. 4313-4316, Vol. 40, No. 11
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.11.4313-4316.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»